Jazz Pharmaceuticals/$JAZZ
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Jazz Pharmaceuticals
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
- Ticker
- $JAZZ
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,890
- Headquarters
- Dublin, Ireland
- Website
- www.jazzpharma.com
JAZZ Metrics
BasicAdvanced
$15B
16.13
$14.63
0.36
-
Price and volume
Market cap
$15B
Beta
0.36
52-week high
$266.38
52-week low
$128.80
Average daily volume
990K
Financial strength
Current ratio
1.779
Quick ratio
1.381
Long term debt to equity
0.704
Total debt to equity
0.918
Interest coverage (TTM)
4.67%
Profitability
EBITDA (TTM)
1,927.067
Gross margin (TTM)
91.35%
Net profit margin (TTM)
20.45%
Operating margin (TTM)
26.28%
Effective tax rate (TTM)
-29.31%
Revenue per employee (TTM)
$1,590,000
Management effectiveness
Return on assets (TTM)
6.86%
Return on equity (TTM)
22.11%
Valuation
Price to earnings (TTM)
16.13
Price to revenue (TTM)
3.164
Price to book
3.19
Price to tangible book (TTM)
-14.88
Price to free cash flow (TTM)
10.487
Free cash flow yield (TTM)
9.54%
Free cash flow per share (TTM)
22.508
Growth
Revenue change (TTM)
12.59%
Earnings per share change (TTM)
-320.62%
3-year revenue growth (CAGR)
6.93%
10-year revenue growth (CAGR)
12.64%
3-year earnings per share growth (CAGR)
120.45%
10-year earnings per share growth (CAGR)
9.78%
What the Analysts think about JAZZ
Analyst ratings (Buy, Hold, Sell) for Jazz Pharmaceuticals stock.
Analyst projections of the future price of Jazz Pharmaceuticals stock.
Bulls say / Bears say
Jazz delivered record second-quarter revenue of $1.21 billion, up 16% year on year, and raised 2026 revenue guidance to $4.60–$4.75 billion. Growth was spread across its sleep, epilepsy and oncology franchises, reducing reliance on any single new launch. (Jazz Pharmaceuticals)
The FDA approved Ziihera for two first-line treatment regimens in HER2-positive gastroesophageal adenocarcinoma. The approval follows Phase 3 data showing a significant overall-survival benefit for the Ziihera, tislelizumab and chemotherapy combination, giving Jazz a potentially important oncology growth engine. (PR Newswire)
Epidiolex remains a growing epilepsy franchise rather than a stagnant mature product: second-quarter sales rose 16% and Jazz is testing it in additional epilepsy populations, including developmental and epileptic encephalopathy, juvenile myoclonic epilepsy and adult Lennox–Gastaut syndrome. (Morningstar)
Xywav is central to Jazz’s sleep franchise, but generic and competing oxybate products are creating a continuing patent and market-share risk. Tris Pharma is challenging multiple Xywav patents, and the litigation has been allowed to proceed. (Legal News Feed, Jazz Pharmaceuticals)
Zepzelca failed to improve overall survival in the Phase 3 LAGOON trial for relapsed small-cell lung cancer. Although its first-line maintenance approval is unaffected, the result weakens the drug’s expansion case in an important oncology indication. (PR Newswire)
Jazz is still carrying material financing risk: it reported about $4.4 billion of long-term debt against roughly $2.2 billion of cash and investments at the end of June, then announced a further $1.0 billion exchangeable-notes offering in August. The extra borrowing can limit flexibility if product growth or acquisitions disappoint. (StockTitan, PR Newswire)
Data summarised monthly by Lightyear AI. Last updated on 27 Sept 2026.
JAZZ Financial Performance
Revenues and expenses
JAZZ Earnings Performance
Company profitability
Upcoming events
No upcoming events
JAZZ News
AllArticlesVideos
Funds containing JAZZ
AllUSDEURGBP
Fund name | Fund size | $JAZZ weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.27% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.27% |
iShares Healthcare Innovation£DRDR | £1B | 1.27% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 1.03% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 1.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.